Sarepta Therapeutics, Inc. (LON:0L35)
54.32
+0.47 (0.87%)
At close: Apr 17, 2025
Sarepta Therapeutics Revenue
In the year 2024, Sarepta Therapeutics had annual revenue of $1.90B USD with 52.97% growth. Sarepta Therapeutics had revenue of $658.41M in the quarter ending December 31, 2024, with 65.94% growth.
Revenue
$1.90B
Revenue Growth
+52.97%
P/S Ratio
2.86
Revenue / Employee
$1.39M
Employees
1,372
Market Cap
4.35B GBP
Revenue Chart
* This company reports financials in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 1.90B | 658.64M | 52.97% |
Dec 31, 2023 | 1.24B | 310.32M | 33.26% |
Dec 31, 2022 | 933.01M | 231.13M | 32.93% |
Dec 31, 2021 | 701.89M | 161.79M | 29.96% |
Dec 31, 2020 | 540.10M | 159.27M | 41.82% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
AstraZeneca | 43.19B |
GSK plc | 31.38B |
Haleon | 11.23B |
Smith & Nephew | 4.64B |
ConvaTec Group | 1.83B |
Hikma Pharmaceuticals | 2.50B |
HUTCHMED (China) | 503.39M |
Oxford Nanopore Technologies | 183.19M |
Sarepta Therapeutics News
- 9 days ago - INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sarepta Therapeutics, Inc. - SRPT - PRNewsWire
- 12 days ago - Sarepta Therapeutics Inc (SRPT) Under Investigation for Potential Securities Law Violations | ... - GuruFocus
- 12 days ago - SRPT Investigation: Kessler Topaz Meltzer & Check, LLP Encourages Sarepta Therapeutics, Inc. (NASDAQ: SRPT) Investors with Significant Losses to Contact the Firm - PRNewsWire
- 15 days ago - NASDAQ: SRPT Investigation Reminder: Kessler Topaz Meltzer & Check, LLP Encourages Sarepta Therapeutics, Inc. (NASDAQ: SRPT) Investors with Significant Losses to Contact the Firm - Business Wire
- 17 days ago - INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sarepta Therapeutics, Inc. - SRPT - GlobeNewsWire
- 20 days ago - Sarepta Therapeutics Stock Falls as Some Trials Halted After Patient Death - Investopedia
- 20 days ago - Sarepta halts three studies testing gene therapy for muscle disorder - Reuters
- 20 days ago - Sarepta Therapeutics Provides Update on ELEVIDYS - Business Wire